Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Neoadjuvant Therapy for Pancreatic Adenocarcinoma
NCT04594772Phase 2Active, not recruiting
- Sponsor
- University of Cincinnati
- Start
- Mar 2021
- Primary completion
- Jun 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FOLFIRINOX, gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by University of Cincinnati. Primary endpoint: Proportion of patients undergoing surgical resection at 16 months. Started Mar 2021; status: active, not recruiting.
02
Drugs
FOLFIRINOXgemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04594772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594772.